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Abstract
Background: The National Research Council (CNR) prostate cancer monitoring project in Italy (Pros-IT CNR) is an
observational, prospective, ongoing, multicentre study aiming to monitor a sample of Italian males diagnosed as
new cases of prostate cancer. The present study aims to present data on the quality of life at time prostate cancer
is diagnosed.
Methods: One thousand seven hundred five patients were enrolled. Quality of life is evaluated at the time cancer
was diagnosed and at subsequent assessments via the Italian version of the University of California Los Angeles-
Prostate Cancer Index (UCLA-PCI) and the Short Form Health Survey (SF-12).
Results: At diagnosis, lower scores on the physical component of the SF-12 were associated to older ages, obesity
and the presence of 3+ moderate/severe comorbidities. Lower scores on the mental component were associated
to younger ages, the presence of 3+ moderate/severe comorbidities and a T-score higher than one.
Urinary and bowel functions according to UCLA-PCI were generally good. Almost 5% of the sample reported using
at least one safety pad daily to control urinary loss; less than 3% reported moderate/severe problems attributable to
bowel functions, and sexual function was a moderate/severe problem for 26.7%. Diabetes, 3+ moderate/severe
comorbidities, T2 or T3-T4 categories and a Gleason score of eight or more were significantly associated with lower
sexual function scores at diagnosis.
Conclusions: Data collected by the Pros-IT CNR study have clarified the baseline status of newly diagnosed prostate
cancer patients. A comprehensive assessment of quality of life will allow to objectively evaluate outcomes of different
profile of care.
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Background
Prostate cancer was the most common cancer diagnosed
in men worldwide in 2015 [1]. With the exclusion of
skin cancers, it represents 20% of all malignancies diag-
nosed in Italian males 50 years old or older [2]. Survival
rates after a prostate cancer diagnosis continue to rise;
approximately 89% of Italian patients are still alive
5 years after diagnosis, with North-western regions
showing better rates with respect to Southern ones [2].
Clinical cancer researchers and oncologists recognize
the importance of measuring survival and the clinical ef-
fects of treatments as well as patients’ quality of life in
terms of subjective perceptions of symptoms, including
physical, emotional and social functions [3, 4]. The in-
creasing numbers of men with prostate cancer diagnoses
and rising life expectancies underscore the importance
of evaluating the quality of life of these patients [5, 6]. A
number of studies have demonstrated that prostate can-
cer and its treatments affect physical and psychological
health, as well as urinary, bowel and sexual function,
with effects that seem to differ depending on the stage
of the disease and the treatment being given [5, 7].
The National Research Council (CNR) prostate cancer
monitoring project in Italy (Pros-IT CNR) is an ongoing
study that is monitoring a sample population of Italian
patients who were enrolled at the time they were diag-
nosed as new cases of prostate cancer. It aims to analyze
the quality of life and general psychological and physical
health parameters in real-world treatment situations
during a 60 month study period. The current article re-
ports on the health and quality of life registered at the
study’s baseline when the patients were newly diagnosed
with prostate cancer.
Methods
Study design
The Pros-IT CNR study design has been described else-
where [8]. Briefly, the Pros-IT CNR is a multicenter, pro-
spective study that aims to monitor the quality of life of
a sample of Italian male patients 18 years and older who
were diagnosed with biopsy-verified treatment-naïve
prostate cancer after September 1, 2014.
Ninety-seven centers including 51 Urology, 39 Radiation
Oncology and 7 Oncological facilities located throughout
Italy were actively involved in the enrollment phase. The
baseline questionnaires were administered at the time
prostate cancer was diagnosed. Six follow-up evaluations
6, 12, 24, 36, 48 and 60 months after the original diagnos-
tic assessment were scheduled for the patients.
Ethics
The Pros-IT CNR study protocol was approved by the
Ethics Committee of the clinical coordinating center lo-
cated at the Sant’Anna Hospital (Como, Italy; register
number 45/2014). It was also approved by the Ethics
Committees of each of the other participating centers.
The study was carried out in accordance with the princi-
ples of the Declaration of Helsinki; all the participants
gave informed consent.
Outcomes measures
Patients’ quality of life was evaluated using the validated
Italian version of the University of California Los
Angeles-Prostate Cancer Index (Italian UCLA-PCI; [9])
and the validated version of the Short Form Health
Survey (SF-12 Standard v1 scale; [10]). Both question-
naires were recommended for use in men with prostate
cancer by the authors of a recent systematic review [11].
The UCLA-PCI which received high ratings for its
psychometric properties (content validity, internal
consistency, construct validity and reproducibility), was
recommended to evaluate health-related quality of life in
prostate cancer patients. UCLA-PCI specifically evalu-
ates urinary function and bother (UF, UB), bowel func-
tion and bother (BF, BB), and sexual function and bother
(SF, SB). Scores range from 0 to 100, with higher score
indicating better conditions.
SF-12 received high ratings for its criterion validity,
construct validity, reproducibility, and interpretability; it
was also recommended in view of its shortness [11]. The
patients’ Physical and mental quality of life (Physical
Component Summary (PCS) and Mental Component
Summary (MCS), respectively) were evaluated using the
SF-12 and possible scores range from 0 to 100, with 100
indicating best self-perceived health. Patients, who were
originally evaluated at the time of diagnosis/enrollment,
and are re-assessed at each of the appointments sched-
uled over the 60-month study period.
Data collection
The participating centers identified eligible patients who
were newly diagnosed with prostate cancer. After signing
the informed consent form, a baseline Data Collection
Form (DCF) was completed by the referring specialist
using a web-platform that was specifically created for
the study. The Italian version of the UCLA-PCI ques-
tionnaire was, instead, printed and completed by each
patient privately, and then returned to the specialist who
loaded the responses into the web-platform.
Statistical analysis
The missing baseline data were analyzed without imput-
ation of missing data.
Categorical variables are presented as numbers and per-
centages. Continuous variables are reported as means and
standard deviations (SD) or medians and interquartile
ranges for skewed variables. Normal distributions of con-
tinuous variables were tested using the Shapiro-Wilk test.
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The patients’ overall quality of life, assessed using the
SF-12 (PCS and MCS), and their quality of life linked to
urinary, bowel and sexual function, assessed using the
Italian version of the UCLA-PCI, were analyzed in relation
to demographic characteristics, risk factors and
disease-staging using a Generalized Linear Model (GLM)
on rank-transformed data, adjusting for age at diagnosis.
Multivariable logistic regression models were defined,
with outcomes the PCS and MCS SF-12 scores as well as
the urinary, bowel and sexual functions of the UCLA-PCI,
dichotomized according to the first quartile of their distri-
bution (Q1). Each model was adjusted for age at diagnosis
(years), education (lower secondary school diploma or less
vs high school diploma or University degree), marital sta-
tus (married or cohabitating vs widowed, divorced or sin-
gle), geographical area of residence (northern regions of
Italy vs central or southern regions), Body Mass Index
(BMI; normal weight vs overweight or obesity), smoking
status (current smoker vs former or never), diabetes melli-
tus, having three or more moderate/severe comorbidities,
T stage (T1 vs T2 or T3-T4) and Gleason score at diagno-
sis (6 vs 3 + 4, 4 + 3, 8+).
All statistical tests were two-tailed, and p-values < 0.05
were considered statistically significant. All the analyses
were performed using the SAS 9.4 statistical software.
Results
One thousand seven hundred fifty-three patientswith a
biopsy-verified prostate cancer were originally enrolled.
Forty-eight protocol violations were registered in relation
to inclusion criteria: diagnoses were formulated before
September 1, 2014 for 35 patients and 13 were not naïve
to prostate cancer treatments. Excluding those patients,
our sample was made up of 1705 patients: 949 (55.7%)
were enrolled in Urology, 717 (42.1%) in Radiation Oncol-
ogy and 39 (2.3%) in Oncological Departments.
More than half of the participants were residing at the
time of diagnosis in Northern Italy, about a quarter in
Central Italy and the rest in Southern regions of the
country. A “health migration” phenomenon was noted in
these patients, as many travelled to centers located in
Table 1 Socio-demographic characteristics and anamnestic data
of the participants of the Pros-IT CNR study at the time they
were diagnosed with prostate cancer
n = 1705
Socio-demographic characteristics at diagnosis
Age at diagnosis, years
mean ± SD 68.9 ± 7.4
min, max 43, 86
Education, n (%)
University degree 103 (12.0)
High school diploma 596 (35.6)
Lower secondary school diploma 393 (23.5)
Elementary license or less 485 (28.9)
Marital status, n (%)
Married or cohabiting 1442 (84.9)
Widowed 98 (5.8)
Separated, divorced or single 159 (9.4)
Living arrangements, n (%)
With spouse and/or children 1535 (90.3)
Alone 165 (9.7)
Work condition, n (%)
Retired 1263 (74.7)
Still working 398 (23.6)
Unemployed 29 (1.7)
Anamnestic data at diagnosis
BMI, n (%)
Under/normal weight (< 25 kg/m2) 568 (34.2)
Overweight (25–29.9 kg/m2) 832 (50.1)
Obesity (≥30 kg/m2) 260 (15.7)
Smoking status, n (%)
Current smoker 230 (13.8)
Former smoker 688 (41.3)
Never smoker 747 (44.9)
Family history of prostate cancer, n (%) 286 (17.0)
Family history of breast cancer, n (%) 80 (5.8)
Family history of ovarian cancer, n (%) 25 (2.1)
Diabetes mellitus, n (%) 263 (15.5)
Patients reporting moderate, severe or extremely severe impairment
for individual CIRS items, n (%)
Cardiac 322 (19.0)
Hypertension 17 (1.0)
Vascular, haematological 464 (27.3)
Respiratory 61 (3.6)
Eye, ear, nose and throat 146 (8.6)
Upper gastrointestinal 236 (13.9)
Lower gastrointestinal 88 (5.2)
Hepatic 110 (6.5)
Table 1 Socio-demographic characteristics and anamnestic data
of the participants of the Pros-IT CNR study at the time they
were diagnosed with prostate cancer (Continued)
n = 1705
Renal 86 (5.1)
Other genitourinary 51 (3.0)
Musculoskeletal, integumentary 82 (3.0)
Neurological, excluding dementia 174 (10.4)
Endocrine, metabolic 83 (4.9)
Psychiatric, behavioural 31 (1.8)
SD Standard Deviation, CIRS Cumulative Illness Rating Scale
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the North to undergo diagnosis and/or treatment. In
fact, 13.7 and 9% of patients residing in the South and
Central areas, respectively, were enrolled at centers lo-
cated in the North.
Socio-demographic characteristics
The main socio-demographic data are presented in
Table 1. The patients’ mean age at diagnosis was 68.9 ±
7.4 years. Almost 12% of the participants had a university
degree, 36% had a high school diploma, and almost 30%
had completed elementary school or had no study degree.
Eighty-five percent of the participants were married or co-
habiting. More than 90% of the participants were living
with other members of their family such as a spouse and/
or children. Approximately three-quarters were retired.
Anamnestic data
More than half of the patients were overweight and had
a BMI between 25 and 29.9 kg/m2 (Table 1). Almost
14% declared that they were current smokers, while 41%
were former smokers.
Seventeen percent of the patients reported having a
family history of prostate cancer; 5.8 and 2.1%, respect-
ively, reported family breast and ovarian cancer history.
The mean age at the diagnosis of prostate cancer in the
participants with a family history of the disease was sig-
nificantly lower than that in those without one (66.8 ± 8.3
vs 69.3 ± 7.2, p < 0.0001).
Two hundred sixty three patients (15.5%) declared
that they had diabetes mellitus. Four hundred
sixty-four of the patients (27.3%) reported having
moderate, severe or extremely severe diseases, as de-
fined by the Cumulative Illness Rating Scale (CIRS;
[12]), of the vascular, lymphatic or hematopoietic sys-
tem; 322 (19.0%) referred having a disease of the car-
diac system, 236 (13.9%) of the gastrointestinal
apparatus and 174 (10.3%) of the neurological system,
excluding dementia.
Fig. 1 Clinical T staging (a) and Gleason score (b) of the participants of the Pros-IT CNR study by age classes at diagnosis
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At enrollment, more than 70% of the participants were
taking at least one medication; the median number of
drugs assumed was three (interquartile range IQ 1–4).
Precisely 53.7% were taking drugs for the circulatory sys-
tem, 27% of the participants were receiving antithrom-
botic agents, 25.4% were medication for the digestive
system and metabolism (16.4% for acidosis, 10.6%
hypoglycemic drugs). About one quarter of the enrolled
patients (22.6%) were taking urological drugs for lower
urinary tract symptoms or for erectile dysfunction.
Diagnosis
The median prostate-specific antigen (PSA) level at diag-
nosis was 7.2 ng/mL (IQ 5.2–10.6). Approximately half
of the study participants had a T1 clinical stage (786,
48%), 38.6 and 11.4% had a T2 or T3-T4clinical stage,
respectively. The Gleason score for prostate biopsy tis-
sue was six for 718 patients (42.8%), 3 + 4 for 381
(22.7%), 4 + 3 for 233 (13.9%) and 8+ for 349 patients
(20.8%). The association of age at diagnosis with both
the clinical T stage and the Gleason score was significant
(p < 0.0001 for trend; Fig. 1a, b).
Quality of life: SF-12
Complete responses to the SF-12 were available for 1664
participants (data was missing for 2.4% of the partici-
pants). The mean PCS value for the entire study popula-
tion was 51.6 ± 7.5; the mean MCS value was 49.3 ± 9.7.
While mean PCS scores tended to be lower in the oldest
patients (p < 0.0001), the mean MCS scores tended to be
higher in the oldest patients (p = 0.0059).
Table 2 outlines the mean PCS and MCS values at
diagnosis analyzed together with other characteristics of
Table 2 Demographic data and responses to the physical (PCS)
and mental components (MCS) of the SF-12 of the participants
of the Pros-IT CNR study at the time they were diagnosed with
prostate cancer
PCS* p-value MCS* p-value
Age at diagnosis
(years)
< 0.0001§ 0.0058§
< 60 54.4 ± 6.2 47.3 ± 9.9
60–64 52.8 ± 6.6 48.5 ± 9.7
65–69 52.2 ± 6.8 50.2 ± 9.3
70–74 51.1 ± 7.7 49.5 ± 10.1
75–79 50.1 ± 8.0 49.9 ± 9.3
80+ 48.1 ± 10.2 49.9 ± 9.0
Education 0.4460 0.5036
University degree 52.7 ± 6.6 49.6 ± 9.4
High school
diploma
52.1 ± 7.2 49.0 ± 9.5
Lower secondary
school diploma
51.2 ± 7.9 49.0 ± 9.8
Elementary license
or less
51.0 ± 7.9 50.0 ± 9.8
Marital status 0.5575 0.4830
Married or
cohabiting
51.8 ± 7.4 49.5 ± 9.4
Widowed 51.1 ± 7.7 49.1 ± 10.2
Separated, divorced
or single
51.1 ± 8.0 48.0 ± 11.0
Geographical area
of residence
0.0002 0.0991
North Italy 51.7 ± 7.5a 49.9 ± 9.6
Central Italy 52.3 ± 7.2b 49.0 ± 9.7
Southern Italy 50.4 ± 7.8ab 48.7 ± 9.8
BMI < 0.0001 0.3796
Under/normal
weight (< 25 kg/m2)
52.0 ± 7.5a 49.1 ± 9.7
Overweight
(25–29.9 kg/m2)
52.0 ± 7.1b 49.5 ± 9.5
Obesity (≥30 kg/m2) 49.7 ± 8.4ab 49.7 ± 9.9
Smoking status 0.1576 0.4419
Non-smoker
or former
51.6 ± 7.6 49.4 ± 9.6
Current smoker 51.9 ± 7.2 48.4 ± 10.1
Diabetes mellitus < 0.0001 0.1894
No 52.0 ± 7.3 49.4 ± 9.7
Yes 49.6 ± 8.4 49.0 ± 9.6
Number of moderate/
severe comorbidities
(according to CIRS)
< 0.0001 < 0.0001
0–2 52.5 ± 6.7 49.8 ± 9.4
3+ 47.0 ± 9.9 46.8 ± 10.4
Table 2 Demographic data and responses to the physical (PCS)
and mental components (MCS) of the SF-12 of the participants
of the Pros-IT CNR study at the time they were diagnosed with
prostate cancer (Continued)
PCS* p-value MCS* p-value
T staging at diagnosis 0.8226 < 0.0001
T1 52.0 ± 7.2 50.4 ± 9.3ab
T2 51.6 ± 7.6 48.7 ± 9.6a
T3 or T4 51.1 ± 7.9 48.6 ± 10.1b
Gleason score
at diagnosis
0.3409 0.1599
6 52.1 ± 7.0 49.6 ± 9.3
3 + 4 51.9 ± 7.3 50.0 ± 9.5
4 + 3 51.6 ± 7.8 48.6 ± 10.3
8+ 50.7 ± 8.3 48.7 ± 10.1
*mean ± SD
§p-value from test for trend
a, bsignificant post-hoc (p < 0.05 adjusting for age at diagnosis)
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the participants. The characteristics associated with
lower PCS scores in the multivariable logistic regression
model were age (Odds Ratio OR 1.06 for each year of
age, 95% Confidence Interval CI 1.04–1.08, p < 0.0001),
obesity (OR 1.84, 95% CI 1.27–2.65, p = 0.0012), the
presence of three or more moderate/severe comorbidi-
ties (OR 2.75, 95% CI 2.01–3.76, p < 0.0001) and a
Gleason score at diagnosis of 8+ (OR = 1.44, 95% CI
1.02–2.05, p = 0.0401). Living in Southern regions of Italy
and being widowed or single were also associated with
lower PCS scores in the multivariable model (OR = 1.69,
95% CI 1.23–2.33, p = 0.0013 and OR= 1.42, 95% CI
1.02–1.98, p = 0.040, respectively).
The characteristics associated with lower MCS scores
in the multivariable logistic model were younger age
(OR = 0.97, 95% CI 0.96–0.98, p = 0.0012), the presence
of three or more moderate/severe comorbidities (OR
1.95, 95% CI 1.42–2.70, p < 0.0001), a T-score at diagno-
sis that was higher than T1 (T2 vs T1 OR 1.51, 95% CI
1.15–1.98, p = 0.0029; T3-T4 vs T1 OR 1.62, 95% CI
1.06–2.48, p = 0.0253).
Quality of life: UCLA-PCI
Complete responses to the UCLA-PCI were available for
1645 participants (3.5% missing data). At the time pros-
tate cancer was diagnosed, urinary function was good
(93.2 ± 15.7) and urinary bother scores were low (88.5 ± 23.3).
Four point 9 % of the study participants reported using
at least one safety pad daily to control urinary loss; the
increase with age was not significant (p = 0.1943): the
percent ranged from 3.2% in the patients younger than
65 to 5.8, 5.3 and 5.4% in the patients between 65 and
69, 70–74 and 75-older, respectively. The use of a daily
safety pad to control urinary loss was significantly
associated with lower urinary bother scores (45.7 ± 29.3
vs 90.7 ± 20.7, p < 0.0001).
Bowel function and bother scores on the UCLA-PCI
were generally good (93.6 ± 13.2 and 93.3 ± 18.3, respect-
ively), and less than 3% of the participants reported a
moderate or severe problem attributable to bowel func-
tion. The mean sexual function and bother scores were
48.6 ± 32.2 and 64.1 ± 35.0, respectively. Twenty-six
point 7 % of the participants declared that their sexual
function was a moderate/large problem: the percentages
ranged from 22.9 to 23.8% to 29.8 and 30.5% in the pa-
tients younger than 65, between 65 and 69, 70–74 or 75
or older respectively (p = 0.0044).
Age was the main characteristic associated with pros-
tate cancer scores (Fig. 2; Table 3), also in the multivari-
able logistic regression models; the p-values for trend
with increasing age were statistically significant for every
health aspect evaluated by UCLA-PCI.
Variables significantly associated with lower scores on
sexual function in the multivariable models were age (OR
1.10, 95% CI 1.08–1.13, p < 0.0001), diabetes (OR = 1.40,
95% CI 1.01–1.96, p = 0.0485), three or more moderate/se-
vere comorbidities according to CIRS (OR 1.55, 95% CI
1.11–2.16, p = 0.0103), T2 or T3-T4 at diagnosis
(OR = 1.42, 95% CI 1.06–1.89, p = 0.0185, and OR = 1.75,
95% CI 1.14–2.69, p = 0.0093, vs T1, respectively) and a
Gleason score of eight or more (OR = 2.03, 95% CI
1.42–2.92, p = 0.0001).
Discussion
The PROS-IT CNR Study allows to assess the quality of
life of males diagnosed as new cases of prostate cancer
in Italy. More than half of the patients reside in
Northern Italy, a fact that is linked to the geography of
the centers, which all voluntarily agreed to participate in
Fig. 2 Mean responses regarding urinary, bowel and sexual function and bother (UCLA-PCI) of the participants of the Pros-IT CNR study by age
classes at diagnosis
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the study. Half, in fact, are located in the North; ap-
proximately a fourth are located in Central Italy and the
rest in the Southern part of the country. According to
the last report of the Italian Association of Cancer Regis-
try (AIRTUM), the standardized incidence of prostate
cancer was inferior in the Southern and Central regions
with respect to that in the Northern ones (68 and 85.7
vs 99.8 per 100,000 men) [2]. Official records also show
that while the Southern part of Italy is characterized by
a lower incidence rate of prostate cancer, it nonetheless
also registers a shorter survival rate. Our study will pro-
vide evidence on potential delay in the diagnosis of pros-
tate cancer in South Italy, which could explain these
epidemiological trends.
The patients participating in the Pros-IT CNR study
were found to be characterized by a higher education
with respect to data referring to the general population
of males over 75 reported by the Italian Statistics Insti-
tute (ISTAT) [13]. While 12% of the men enrolled in our
study had a university degree, only 7% of the general
population did so. While 30% of the participants com-
pleted grade school or had no official schooling, 48.6%
of the general male elderly population did so. The differ-
ences in educational status of the participants and the
general population, seem to suggest that socio-economic
characteristics might be associated to the risk of prostate
cancer in the Italian population. We cannot however ex-
clude a selection bias as more highly educated males
may have agreed to participate in the study.
The mean score physical SF-12 component score was
51.7, which was higher than that described by the ISTAT
in males between 65 and 74 (48.4) or those over 75
(41.5). The scores on the emotional-psychological SF-12
component in the participants were consistent with
those reported by the ISTAT in males between 65 and
74 and slightly higher than those calculated for men over
75 [13]. These results disagree to some extent with what
has been reported by other studies. For example, both
the investigators of the ProtecT trial and a review on
prostate cancer and health-related quality of life, re-
ported scores on the two SF-12 components in just diag-
nosed patients that were consistent with those in the
population at large [5, 7]. Moreover, according to other
studies, just diagnosed with prostate cancer patients had
lower scores on the emotional-psychological component
with the respect to those in the general population [14,
15]. Again, these results could be explained by the
higher level of education of the participants in our sam-
ple compared to that of the general population, a factor
that is usually associated to an overall better physical
and emotional health.
The scores on the physical component and thus con-
cerning the perception of physical health were worse, in
our study, in the older age-groups, while those concerning
emotional-psychological status tended to be worse in the
youngest age-group, suggesting, just as has been point out
in other studies, that a certain amount of psyco-emotional
adjustment takes place with aging [16, 17].
It is interesting that worse emotional-psychological
component scores were associated to worse T classes at
diagnosis regardless of age or other confounding factors
such as comorbidities. Likewise, worse T or Gleason
scores at diagnosis were associated to worse scores on
sexual function, although in some studies men with lo-
calized prostate cancer reported more sexual problems
with respect to same-age peers without cancer [3].
Approximately 5% of the patients included in our
study declared that they used at least one safety pad
daily to control urinary loss. That percentage did not
change in the older patients, but it did when there were
other urinary disturbances. This baseline finding is of
primary relevance when post-treatment continence is
being defined and evaluated.
The Pros-IT CNR study has several strengths, includ-
ing its multidisciplinary approach and its prospective de-
sign. The study’s longitudinal design that foresees
monitoring the participants for 60 months from the time
of diagnosis, will allow to evaluate the disease’s evolution
over time and the patients quality of life. One of the
study’s limitations instead is connected to the fact that
centres were involved on a voluntary basis and a selec-
tion bias cannot be excluded.
Conclusions
The importance of the results presented here is twofold:
they draw a profile of the general state of health and the
subjective perception of quality of life of patients who
have just been diagnosed with prostate cancer. More-
over, they underscore the patients’ characteristics at
diagnosis that are relevant for appreciating the variations
over time of their quality of life. More detailed know-
ledge about patients’ pre-treatment status and percep-
tion of health and quality of life will be essential to
evaluate their response to treatment and to permit us to
compare our data with those reported by other studies.
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